Spectral AI (MDAI) said Tuesday it has completed its pediatric enrollment at US emergency departments for its burn treatment pivotal study.
The study aims to validate the artificial intelligence-driven algorithm used by the company's DeepView System, a device that uses multi-spectral imaging and algorithms to predict burn healing potential, according to the company.
Spectral AI said it plans to use the results of the study to support its De Novo classification request, expected to be submitted to the US Food and Drug Administration within H1.
Price: 1.79, Change: +0.03, Percent Change: +1.65
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。